Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SMITHKLINE-BEECHAM TUMS SALES REACH $138.9 MIL.

This article was originally published in The Tan Sheet

Executive Summary

SMITHKLINE-BEECHAM TUMS SALES REACH $138.9 MIL. in food and drug stores combined for the 12 months ended June 30, according to Information Resources' subsidiary Towne-Oller. Sales for the antacid leader through June were up 15% compared to a year ago, the data show. Tums held a 17.7% share of the broad antacid market tracked by Towne-Oller, which includes products with additional indications outside the antacid area such as Procter & Gamble's Pepto-Bismol and McNeil's Lactaid for lactose intolerance.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS083077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel